Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

Delayed Quote. Delayed  - 07/22 10:00:00 pm
6.53 USD   +0.46%
07/13 SPECTRUM PHARMA : Settles FOLOTYN® (pralatrexate injection) ANDA Pat..
07/11 SPECTRUM PHARMA : Biotechnology Stocks Under the Scanner -- PTC Ther..
07/06 SPECTRUM PHARMA : to Present Corporate Update at the Cantor Fitzgera..
News SummaryMost relevantAll newsSector news 

Spectrum Pharmaceuticals, Inc. : Hagens Berman Notifies Spectrum Pharmaceuticals Investors of Pending Class-Action Lawsuit and May 13, 2013, Lead Plaintiff Deadline

share with twitter share with LinkedIn share with facebook
share via e-mail
03/22/2013 | 02:35pm CEST

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or "The Company") following the filing of a class-action lawsuit on behalf of investors. The firm encourages those who have suffered losses to contact Hagens Berman Partner Reed Kathrein, who is leading the Firm's investigation, by emailing SPPI@hbsslaw.com.

A class-action lawsuit filed in U.S. District Court identifies a class of Spectrum investors who purchased stock in the company between August 8, 2012, and March 12, 2013, inclusive (the "class period"). Those who suffered significant losses and wish to move to be a lead plaintiff may also contact the firm by calling (510) 725-3000.

Investors who wish to serve as lead plaintiff in the case must move the court no later than May 13, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

On March 12, 2013, Spectrum disclosed to investors that it would significantly lower its 2013 revenue guidance on concerns that sales of its drug FUSILEV would be lower than expected. Following the disclosure, Spectrum's stock price fell dramatically, from a close of $12.43 per share on March 12 to a close of $7.79 per share on March 13. The stock has continued to trade at or around $7.00 since the disclosure.

Hagens Berman's investigation centers around whether Spectrum knew and failed to disclose to investors concerns about the sales of FUSILEV.

"We are concerned that Spectrum knew that generic competition would substantially impact the company's revenues and failed to disclose these concerns to investors," said Mr. Kathrein. "We believe the company's alleged failure to come clean with investors about these issues may have artificially inflated the stock price, resulting in very significant investor losses."

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

More information about this investigation is available at http://www.hb-securities.com/investigations/SPPI.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hbsslaw.com. The Firm's securities law blog is at http://www.meaningfuldisclosure.com.

Firmani + Associates
Mark Firmani, 206-443-9357

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
07/13 SPECTRUM PHARMACEUTICALS : Settles FOLOTYN® (pralatrexate injection) ANDA Patent..
07/13 SPECTRUM PHARMACEUTICALS INC : Other Events (form 8-K)
07/11 SPECTRUM PHARMACEUTICALS : Biotechnology Stocks Under the Scanner -- PTC Therape..
07/06 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Cantor Fitzgerald'..
07/06 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Cantor Fitzgerald&..
07/01 SPECTRUM PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holde..
06/09 SPECTRUM PHARMACEUTICALS INC : Other Events (form 8-K)
06/09 SPECTRUM PHARMACEUTICALS : Highlights an Oral Presentation on Apaziquone at the ..
06/01 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Jefferies 2016 Hea..
05/31 SPECTRUM PHARMACEUTICALS INC : Other Events (form 8-K)
More news
Sector news : Biotechnology & Medical Research - NEC
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/13 Spectrum Pharmaceuticals settles Folotyn patent fight with Fresenius
06/09 Spectrum and Sandoz settle Folotyn patent patent suit, Sandoz OK to sell gene..
05/25 Spectrum Pharma settles Folotyn patent squabble with Teva
05/05 Spectrum Pharmaceuticals' (SPPI) CEO Rajesh Shrotriya on Q1 2016 Results - Ea..
05/05 Spectrum Pharmaceuticals beats by $0.18, beats on revenue
Financials ($)
Sales 2016 134 M
EBIT 2016 -56,1 M
Net income 2016 -84,4 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 3,37x
Capi. / Sales 2017 3,96x
Capitalization 452 M
More Financials
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Full-screen chart
Technical analysis trends SPECTRUM PHARMACE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 9,33 $
Spread / Average Target 43%
Consensus details
EPS Revisions
More Estimates Revisions
Rajesh C. Shrotriya Chairman & Chief Executive Officer
Joseph G. Turgeon President & Chief Operating Officer
Kurt A. Gustafson Chief Financial Officer, CAO & Executive VP
Stuart Mitchell Krassner Director
Anthony E. Maida Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%10 689
LONZA GROUP AG9.44%9 737
ALKERMES PLC-37.26%7 528
More Results